Who are pirarubicin and cyclophosphamide's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pirarubicin-and-cyclophosphamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

pirarubicin and cyclophosphamide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

pirarubicin and cyclophosphamide (pirarubicin and cyclophosphamide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anthracycline and alkylating agent combination. Area: Oncology.

marketed Anthracycline and alkylating agent combination DNA (topoisomerase II for pirarubicin; DNA alkylation for cyclophosphamide) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

pirarubicin and cyclophosphamide (pirarubicin and cyclophosphamide) — Hebei Medical University Fourth Hospital. Pirarubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II, while cyclophosphamide is an alkylating agent that cross-links DNA, together inducing cancer cell death.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
pirarubicin and cyclophosphamide TARGET	pirarubicin and cyclophosphamide	Hebei Medical University Fourth Hospital	marketed	Anthracycline and alkylating agent combination	DNA (topoisomerase II for pirarubicin; DNA alkylation for cyclophosphamide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anthracycline and alkylating agent combination class)

Hebei Medical University Fourth Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). pirarubicin and cyclophosphamide — Competitive Intelligence Brief. https://druglandscape.com/ci/pirarubicin-and-cyclophosphamide. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab